<DOC>
	<DOCNO>NCT02454478</DOCNO>
	<brief_summary>Phase 1 study investigate tolerability safety lenvatinib combination Everolimus participants unresectable advanced metastatic RCC .</brief_summary>
	<brief_title>Study Lenvatinib Combination With Everolimus Patients With Unresectable Advanced Metastatic Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Voluntary agreement provide write informed consent study 2 . Willing able comply aspect protocol fully inform content 3 . Males female age great equal 20 year time inform consent 4 . Histological cytological confirmation RCC 5 . Participants must confirm diagnosis unresectable advanced and/or metastatic RCC 6 . Disease progression follow VEGF target therapy 7 . ECOGPS 0 1 8 . Adequately control blood pressure without use antihypertensive agent 9 . Participants adequate function major organ 10 . Adequate blood coagulation function , define international normalized ratio ( INR ) less equal 1.5 11 . Survival expectation 3 month longer study enrollment 12 . Participants adequate washout period end prior treatment start study drug administration 13 . Females childbearing potential must unprotected sexual intercourse within 28 day participant registration must agree use highly effective method contraception throughout entire study period 30 day final administration investigational drug . If currently abstinent , participant must agree use doublebarrier method describe becomes sexually active study period 30 day investigational drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week administration must continue use contraceptive study 30 day investigational drug discontinuation . 14 . Male participant female partner must meet criterion 1 . Participants CNS metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment study . Any sign ( eg , radiologic ) symptom brain metastasis must stable least 4 week start study treatment . 2 . Prior exposure lenvatinib 3 . Participants recover toxicity less equal Grade 1 result prior anticancer therapy , except alopecia 4 . Major surgery within 3 week prior first dose lenvatinib 5 . Participants urine protein great equal 1g/24 hour 6 . Uncontrollable diabetes define fast glucose great 1.5 X ULN 7 . Fasting total cholesterol great 7.75 mmol/L ( great 300 mg/dL ) 8 . Fasting triglyceride great 2.5 X ULN 9 . Any condition might affect absorption lenvatinib and/or everolimus 10 . Significant cardiovascular impairment 11 . Bleeding thrombotic disorder use anticoagulant require therapeutic INR monitoring 12 . Active hemoptysis 13 . Active infection require systemic treatment 14 . Human immunodeficiency virus ( HIV ) positive 15 . Hepatitis B virus ( HBV ) 16 . A history interstitial pneumonia clinical manifestation confirm mean diagnostic image 17 . Medical need continue use potent moderate inhibitor CYP3A Pgp , potent moderate inducer CYP3A 18 . Known intolerance lenvatinib ( excipients ) know hypersensitivity everolimus ( excipients ) rapmycins ( sirolimus , temsirolimus ) 19 . Alcohol drug dependency abuse , inability comply every aspect study protocol , physical mental condition opinion investigator would preclude participant 's participation study 20 . Females pregnant breastfeeding ( eligible even discontinues breastfeed ) 21 . Any medical condition , opinion investigator , would preclude participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>lenvatinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Unresectable advance renal cell carcinoma</keyword>
	<keyword>Metastatic renal cell carcinoma</keyword>
</DOC>